Pharmaceutical company Divi’s Laboratories Limited on Monday recorded profit for the quarter ended September 2023 at Rs 348 crore, down 29.4 per cent as against Rs 493 crore during the corresponding quarter of FY23, missing estimates. It posted revenue from operations at Rs 1909 crore, up 2.9 per cent in comparison to Rs 185 crore during the second quarter of FY23. According to a CNBC TV18 poll, Divi’s Laboratories was expected to post Q2 profit at Rs 410.8 crore and revenue for the quarter in review was estimated to come at Rs 1886 crore. The company EBITDA stood at Rs 479 crore.
For the current quarter, the company have a forex gain of Rs 11 crore as against a gain of Rs 31 crore during the corresponding quarter of last year.
For the half-year ended 30th September, 2023, Divi’s Laboratories recorded a consolidated total income of Rs 3854 crore as against a consolidated total income of Rs 4278 crore during the previous half-year. PAT for the current half-year came to Rs 704 crore as against Rs 1196 crore for the previous half-year. “For the current half-year, we had a forex gain of Rs 14 crore as against a gain of Rs 87 crore during the corresponding period last year,” it said.